First Time Loading...

Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 89.78 CHF 1.91% Market Closed
Updated: May 8, 2024
Section:
 

Relative Value

The Relative Value of one NOVN stock under the Base Case scenario is 99.68 CHF. Compared to the current market price of 89.78 CHF, Novartis AG is Undervalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVN Relative Value
Base Case
99.68 CHF
Undervaluation 10%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
4
vs Industry
30
Median 3Y
3.6
Median 5Y
3.6
Industry
2.5
Forward
4.1
More Details
13.6
P/E
P/E
Price to Earnings
13.6
vs History
74
vs Industry
33
Median 3Y
17.2
Median 5Y
15.7
Industry
23.4
Forward
13.8
More Details
14
P/OCF
P/OCF
Price to OCF
14
vs History
15
vs Industry
29
Median 3Y
13
Median 5Y
12.9
Industry
17.4
More Details
22.3
P/FCFE
P/FCFE
Price to FCFE
22.3
vs History
53
vs Industry
22
Median 3Y
22.8
Median 5Y
22.4
Industry
23.6
More Details
4.3
P/B
P/B
Price to Book Value
4.3
vs History
9
vs Industry
17
Median 3Y
3.5
Median 5Y
3.3
Industry
2.1
More Details
4.5
EV/S
EV/S
Enterprise Value to Sales
4.5
vs History
4
vs Industry
28
Median 3Y
4
Median 5Y
4
Industry
2.6
Forward
4.2
More Details
6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6
vs History
6
vs Industry
37
Median 3Y
5.4
Median 5Y
5.5
Industry
5.2
More Details
9.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.9
vs History
77
vs Industry
35
Median 3Y
10.1
Median 5Y
10.5
Industry
13.7
Forward
10.5
More Details
16.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.4
vs History
50
vs Industry
29
Median 3Y
16.1
Median 5Y
16.3
Industry
17.2
Forward
12.9
More Details
14.4
EV/OCF
EV/OCF
Enterprise Value to OCF
14.4
vs History
31
vs Industry
30
Median 3Y
13.4
Median 5Y
13.6
Industry
16.2
More Details
17.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.8
vs History
25
vs Industry
23
Median 3Y
16.4
Median 5Y
16.5
Industry
17.8
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
4
vs Industry
32
Median 3Y
1.9
Median 5Y
1.8
Industry
2
More Details

Multiples Across Competitors

NOVN Competitors Multiples
Novartis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Novartis AG
SIX:NOVN
183.4B CHF 4.3 13.6 9.9 16.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
733.8B USD 20.4 119.5 58.5 66.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.9 46.8 34.2 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
358.4B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
326B USD 5.3 141.4 35.2 57.5
UK
AstraZeneca PLC
LSE:AZN
187.8B GBP 4.9 37.1 173.5 276.8
CH
Roche Holding AG
SIX:ROG
176.5B CHF 3 15.4 8.7 10.4
US
Pfizer Inc
NYSE:PFE
158.6B USD 2.9 -513.2 12.7 20.3
FR
Sanofi SA
PAR:SAN
115.2B EUR 2.5 21.3 8.1 11.8
P/E Multiple
Earnings Growth
CH
Novartis AG
SIX:NOVN
Average P/E: 50.5
13.6
15%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.5
346%
DK
Novo Nordisk A/S
CSE:NOVO B
46.8
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
141.4
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.1
168%
CH
Roche Holding AG
SIX:ROG
15.4
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -513.2
680%
FR
Sanofi SA
PAR:SAN
21.3
120%

See Also

Summary
NOVN intrinsic value, competitors valuation, and company profile.
DCF Valuation
NOVN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NOVN stock valuation using valuation multiples.
Wall Street Estimates
NOVN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NOVN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.